Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20487312 | 0.91 | LMNA (0.38) | LMNAALOX15ALDH1A1PTGDR2CFD | |
| SCHEMBL20487966 | 0.89 | LMNA (0.37) | LMNAALDH1A1PTGDR2CFDMEN1 | |
| SCHEMBL23629630 | 0.88 | LMNA (0.36) | LMNAKDM4EPTGDR2CFDKRAS | |
| SCHEMBL20487269 | 0.86 | LMNA (0.41) | LMNAALOX15ALDH1A1PTGDR2CFD | |
| SCHEMBL25930232 | 0.84 | MTNR1A (0.33) | ALDH1A1KDM4E | |
| SCHEMBL29468351 | 0.84 | MTNR1A (0.33) | ALDH1A1KDM4E | |
| SCHEMBL20488677 | 0.83 | LMNA (0.43) | LMNAALOX15ALDH1A1PTGDR2KRAS | |
| SCHEMBL20488553 | 0.83 | LMNA (0.33) | LMNAKDM4EMAPK1MEN1KMT2A | |
| SCHEMBL20488090 | 0.82 | EPRS1 (0.35) | LMNAALDH1A1TSHRPTGDR2CFD | |
| SCHEMBL20488179 | 0.81 | LMNA (0.34) | LMNAPTGDR2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3985002-A1 | ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018160889-A1 | ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | LMNA 2273/4885ALOX15 189/4885ALDH1A1 2545/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | LMNA 2135/4885ALOX15 123/4885ALDH1A1 2338/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | LMNA 2135/4885ALOX15 123/4885ALDH1A1 2338/4885 |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | LMNA 2135/4885ALOX15 123/4885ALDH1A1 2338/4885 |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | LMNA 2135/4885ALOX15 123/4885ALDH1A1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.